Ligand Pharmaceuticals Incorporated LGND announced that
the U.S. Food and Drug Administration (FDA) has granted orphan-drug
designation for its proprietary Captisol-enabled™ Topiramate Injection
for the treatment of partial onset or primary generalized tonic-clonic
seizures in hospitalized epilepsy patients who are unable to take oral
topiramate.
“The granting of orphan designation for Ligand's Captisol-enabled
Topiramate program is an important step in the future of this
potentially life-saving therapeutic, and should provide an additional
layer of market exclusivity for the program,” commented Matthew W.
Foehr, Executive Vice President and Chief Operating Officer of Ligand.
“In Phase 1 trials in healthy volunteers and patients at the University
of Minnesota, this product
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in